Get started
Author

Nozibusiso Rejoice Mosia

Observed names: Nozibusiso Rejoice Mosia, Nozibusiso Mosia, Nozibusiso R Mosia
OpenAlex ID: A5073735749
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial
2025 · Javed Butler, Ciaran J McMullan, et al. · The Lancet · 92
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials
2025 · Faiez Zannad, Christopher M O'Connor, et al. · The Lancet · 50
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
2023 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 12
PDF
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study
2025 · Anushka Naidoo, Hylke Waalewijn, et al. · The Lancet HIV · 5
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial
2025 · Lisanne A.H. Bevers, Lisanne A.H. Bevers, et al. · EBioMedicine · 3
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
2026 · Diana Anena, Elizabeth Chappell, et al. · Contemporary Clinical Trials · 2
Neuropsychiatric Manifestations and Sleep Disturbances in Children and Adolescents Randomised to Dolutegravir-Based Antiretroviral Therapy vs Standard-of-Care in the Odyssey Trial
2023 · Anna Turkova, Ellen White, et al. · SSRN Electronic Journal · 1
Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
2026 · Mutsa Bwakura-Dangarembizi, Elizabeth Chappell, et al. · The Lancet
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial
2026 · Adeodata R Kekitiinwa, Angus Jennings, et al. · The Lancet HIV
Works count: 9
Citation count: 165
H-index: 4
I10-index: 3
Year
Topic
Type